Edap TMS SA
EDAP TMS SA develops and commercializes minimally invasive medical systems, centered on its Focal One robotic high-intensity focused ultrasound (HIFU) platform for prostate care. The company also has legacy lithotripsy (ESWL) and medical device distribution activities, with operations and sales across the United States, Europe, and other international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRobotic HIFU systems, disposables, RPP arrangements, leases, and related services.
Maintenance contracts and support services for installed Focal One systems.
Legacy lithotripsy consumables, spare parts, repair services, and residual system activity.
Third-party medical device distribution and related consumables, leasing, and services.
Products
Reported · share of revenue- Manufactured Product Other69.3 %
- Parts and Services16.1 %
- HIFU Treatments and Devices Leased14.6 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
EDAP sells primarily to hospitals, urology centers, and other healthcare providers that treat prostate and stone disease. Its HIFU business serves providers that want a robotic, minimally invasive therapy platform, while the RPP and lease models appeal to customers that prefer usage-based or lower upfront payment structures. The ESWL and distribution businesses serve installed-base users and healthcare buyers needing consumables, parts, and third-party devices.
Buy Focal One systems and related services to add minimally invasive prostate treatment capability.
Use RPP and lease arrangements to access HIFU technology with lower upfront capital needs.
Purchase consumables, spare parts, and repairs for existing lithotripsy systems.
Buy third-party devices and related consumables through the distribution channel.
Strategy
EDAP’s strategy is centered on expanding its proprietary HIFU franchise and reducing reliance on legacy ESWL and distribution activities. The company is building installed base, treatment-driven revenue, and recurring service streams while continuing to invest in commercialization and product development. This mix is intended to strengthen the long-term profile of the business around a differentiated medical technology platform.
HIFU is the core proprietary platform and the main driver of future growth.
RPP, leases, disposables, and maintenance reduce dependence on one-time equipment sales.
ESWL and distribution are lower-priority activities and less central to the company’s platform strategy.
Geography
Q2/2026EDAP has a multinational footprint, with meaningful activity in the United States and Europe and additional sales in other jurisdictions. The company uses different commercial models by region, including operating leases in the U.S. and RPP arrangements in Europe, which affects revenue timing and predictability. Its installed base and sales mix also create exposure to local reimbursement, regulatory, and adoption patterns in each market.
Share of the revenue the company reports by geography.
Risks
EDAP depends on adoption of a specialized medical technology, so demand can be affected by hospital capital budgets, clinical acceptance, and reimbursement dynamics. The business also faces execution risk from its mix of equipment sales, leases, RPP contracts, and recurring service revenue, plus exposure to foreign exchange, tariffs, and regulatory requirements across markets.
The growth strategy relies on hospitals and clinics adopting Focal One and treatment workflows.
Exposure: U.S. and Europe commercialization
Commercialization and R&D needs may require additional capital if operating cash generation is insufficient.
Exposure: Corporate funding
ESWL system sales have ended and distribution agreements have been terminated, reducing legacy revenue streams.
Exposure: ESWL and Distribution divisions
Operating leases and revenue-per-procedure models spread revenue over time and can create quarter-to-quarter volatility.
Exposure: HIFU division
The company operates internationally and has disclosed tariff impact and euro-dollar sensitivity.
Exposure: Europe and cross-border supply chain
Accounting
Judgemental itemsFocal One sales, leases, RPP, disposables, and services are recognized differently and affect timing of revenue.
Impact: Can shift revenue between quarters and change gross margin mix
The company records fair value changes on EIB warrants and related financing items.
Impact: Can create volatility in non-operating income or expense
International operations expose the company to euro-dollar and other currency movements.
Impact: Can materially affect reported earnings and cash balances
Operating leases for Focal One systems affect revenue timing and asset/liability presentation.
Impact: Influences balance sheet structure and recurring revenue profile
Similar listed companies
Publicly listed companies with a comparable business focus.
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
Microbot Medical Inc.
MBOT · Surgical & Medical Instruments & Apparatus
PROCEPT BioRobotics Corp
PRCT · Surgical & Medical Instruments & Apparatus
PROCEPT BioRobotics Corp develops and commercializes robotic systems for urology procedures, centered on Aquablation therapy for benign prostatic hyperplasia (BPH).
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Intuitive Surgical, Inc
ISRG · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Intuitive Surgical designs and sells robotic-assisted surgical systems and related instruments, accessories, software, and services used to perform minimally invasive procedures.
Baird Medical Investment Holdings Ltd
BDMD · Surgical & Medical Instruments & Apparatus
Baird Medical Investment Holdings Ltd is a U.S.-listed medical device company focused on minimally invasive ablation technologies for solid tumors.
Last updated: 24/09/2026